Suppr超能文献

治疗性血液成分单采术的范围及应用:来自印度北部一家三级医疗中心的经验

Scope and application of therapeutic apheresis: Experience from a tertiary care hospital in North India.

作者信息

Sharma Ratti Ram, Saluja Karan, Jain Ashish, Dhawan Hari Krishan, Thakral Beenu, Marwaha Neelam

机构信息

Dept. of Transfusion Medicine PGIMER, Chandigarh 160012, India.

出版信息

Transfus Apher Sci. 2011 Dec;45(3):239-45. doi: 10.1016/j.transci.2011.09.002. Epub 2011 Oct 28.

Abstract

BACKGROUND

We present here our experience with therapeutic apheresis (TA) performed for various indications, clinical response and complications in a tertiary care center over last 10 years.

STUDY DESIGN AND METHODS

Present study is a retrospective analysis of 492 TA procedures performed for 125 patients from January 2000 to December 2009. For each patient: age, gender, weight, clinical indication, pre-procedure hematological profile and ionized calcium levels were recorded. For every procedure following parameters were analyzed: type of venous access (central/peripheral), volume of blood and plasma processed, amount of anticoagulant used, procedure duration, blood flow rate, type of replacement fluid given, response to therapy and adverse reactions.

RESULTS

Of 492 TA procedures, 68.8% were performed for neurology, 20.8% hematology-oncology, 9.6% renal and 0.8% for rheumatology patients. Therapeutic plasma exchanges (n=464; 94.3%) and therapeutic cytapheresis (n=28; 6.7%) were performed in 113 and 12 patients, respectively. Majority of patients belonged to ASFA category I and II (n=124; 99.2%). The overall response rate was 84%, with encouraging response in TTP (100%), aHUS (81.8%) and in neurological disorders (88.4%). Adverse events were reported in 52.8% of patients in 14.83% of procedures.

CONCLUSION

Our results of TPE in neurological disorders and in atypical hemolytic uremic syndrome are encouraging and it is a cost effective alternative to IvIg in neurological disorders. Currently, there is a need for establishment of an Indian apheresis registry to understand the scenario of TA across the country and in the expansion of appropriate and applicable indications for TA in our setting.

摘要

背景

我们在此介绍过去10年在一家三级医疗中心针对各种适应症、临床反应及并发症进行治疗性血液成分单采(TA)的经验。

研究设计与方法

本研究是对2000年1月至2009年12月期间为125例患者进行的492次TA程序的回顾性分析。记录每位患者的年龄、性别、体重、临床适应症、术前血液学指标及离子钙水平。对每次程序分析以下参数:静脉通路类型(中心/外周)、处理的血液和血浆量、抗凝剂用量、程序持续时间、血流速度、给予的置换液类型、治疗反应及不良反应。

结果

在492次TA程序中,68.8%用于神经科患者,20.8%用于血液肿瘤学,9.6%用于肾脏疾病,0.8%用于风湿病患者。分别对113例和12例患者进行了治疗性血浆置换(n = 46,4;94.3%)和治疗性血细胞单采(n = 28;6.7%)。大多数患者属于美国单采学会(ASFA)I类和II类(n = 124;99.2%)。总体反应率为84%,在血栓性血小板减少性紫癜(TTP,100%)、非典型溶血尿毒综合征(aHUS,81.8%)和神经系统疾病(88.4%)中反应令人鼓舞。52.8%的患者在14.83%的程序中报告了不良事件。

结论

我们在神经系统疾病和非典型溶血尿毒综合征中进行治疗性血浆置换(TPE)的结果令人鼓舞,并且在神经系统疾病中它是静脉注射免疫球蛋白(IvIg)的一种经济有效的替代方法。目前,有必要建立一个印度单采登记处,以了解全国TA的情况,并在我们的环境中扩大TA的适当和适用适应症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验